BTK Inhibitors and Multiple Sclerosis

Therapeutic Potential of BTK Inhibitor Tolebrutinib in NonRelapsing Secondary Progressive MSПодробнее

Remyelination for MS: Remyelination Clincal Trials & more! - MS ExerciseПодробнее

Multiple Sclerosis RESEARCH BREAKTHROUGH!Подробнее

Understanding smoldering pathology in MSПодробнее

An update on research in BTK inhibitors for the treatment of MSПодробнее

What's New in the Fight Against Multiple Sclerosis? 🔍 Watch @nucleotides_orgПодробнее

Challenges and Potential of BTK Inhibitors in MS TreatmentПодробнее

Potential of BTK Inhibitors for Primary Progressive Multiple SclerosisПодробнее

Tolebrutinib Effective for Secondary Progressive Multiple Sclerosis (Sanofi Press Release)Подробнее

2023 endMS Conference - Dr. Mark Freedman: Advancements in MS TreatmentsПодробнее

Addressing the Unmet Needs of Managing MS SymptomsПодробнее

MS and Evobrutinib’s Phase III “Fail”Подробнее

BTK inhibitors for MS treatment: what do the recent trial readouts mean for the field?Подробнее

2023 Multiple Sclerosis Research RoundupПодробнее

Research Update: Clinical Trials for Multiple SclerosisПодробнее

Failed Clinical Trial for BTK inhibitor?! WTH?!Подробнее

2023 MS Symposium (Part 5 of 5) - The Power of the Patient -Taking MS into your hands + much MoreПодробнее

Ben Thrower, MD: Ask the MS Expert: April 2024Подробнее

Updates on BTK inhibitor safety in multiple sclerosisПодробнее

Aaron Boster, MD: Ask the MS Expert: November 2023Подробнее